ANCA-associated vasculitis (AAV) is a rare autoimmune condition causing inflammation of small and medium blood vessels, potentially damaging vital organs like kidneys and lungs. While there’s no cure, treatment is highly effective at controlling the disease and preventing life-threatening complications. Therapy isn’t one-size-fits-all; it’s tailored to the individual’s symptoms, affected organs, and specific immune markers. Treatment typically follows a two-phase process: induction to achieve remission, followed by maintenance to prevent relapse.
Phase 1: Induction Therapy – Rapidly Stopping the Inflammation
When AAV is first diagnosed, aggressive treatment is often necessary to quickly halt the inflammation that’s already causing organ damage. Doctors describe this as “pulling the fire alarm” – using potent medications to dampen the immune response and induce remission. This phase typically lasts 3–6 months and may involve:
- High-Dose Corticosteroids (Prednisone, Methylprednisone): These rapidly reduce inflammation but are usually combined with other drugs due to side effects and tapered quickly.
- Rituximab (Rituxan): A standard first-line treatment administered by IV infusion. It’s often used with steroids, but takes time to become effective.
- Cyclophosphamide (Cytoxan): A chemotherapy drug effective for remission, but used less frequently now due to side effects.
- Benralizumab (Fasenra) & Mepolizumab (Nucala): Newer injectable biologics specifically for eosinophilic granulomatosis with polyangiitis (EGPA), a form of AAV affecting the lungs.
- Methotrexate & Mycophenolate Mofetil (CellCept): Used in milder cases, but may carry a higher relapse risk.
- Avacopan (Tavenos): A newer drug approved to reduce or replace long-term steroid use.
While these medications are generally safe when properly monitored, they can cause side effects like infections, weight gain, mood swings, and increased blood pressure.
Phase 2: Maintenance Therapy – Guarding Against Relapse
Even after achieving remission, up to 90% of AAV patients will relapse without ongoing treatment. The transition from induction to maintenance requires careful timing to ensure disease control while minimizing side effects. Maintenance therapy involves lower doses or less frequent administrations of drugs used in induction, such as:
- Rituximab
- Methotrexate
- Azathioprine (Imuran)
- Low-Dose Prednisone
Patients on maintenance therapy may experience occasional gastrointestinal side effects and require regular blood monitoring. Long-term steroid use can lead to complications like insulin resistance, bone loss, and glaucoma.
Shared Decision-Making: A Collaborative Approach
Effective AAV management requires open communication between patient and doctor. Discussing treatment options, lifestyle considerations, and potential risks is crucial. Treat AAV as a chronic condition, similar to diabetes or high blood pressure, with regular check-ups and medication adherence.
The key takeaway is this: AAV treatment is a two-phase process. Aggressive induction aims to quickly control the disease, while long-term maintenance prevents relapse. Consistent monitoring and proactive communication with your healthcare team are essential for managing this complex condition.
